Positive News SentimentPositive NewsNASDAQ:CRIS Curis (CRIS) Stock Forecast, Price & News $0.82 -0.01 (-1.20%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$0.79▼$0.8450-Day Range$0.55▼$0.9952-Week Range$0.47▼$1.77Volume199,750 shsAverage Volume435,637 shsMarket Capitalization$79.40 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Curis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside995.2% Upside$9.00 Price TargetShort InterestHealthy2.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector728th out of 981 stocksBiological Products, Except Diagnostic Industry119th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Curis has a forecasted upside of 995.2% from its current price of $0.82.Amount of Analyst CoverageCuris has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.29% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Curis has recently decreased by 0.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRIS. Previous Next 2.6 News and Social Media Coverage News SentimentCuris has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Curis this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Curis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.33% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 38.72% of the stock of Curis is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Curis are expected to remain at ($0.47) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Curis (NASDAQ:CRIS) StockCuris, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.Read More Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Stock News HeadlinesJune 6, 2023 | finance.yahoo.comIs Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount?May 15, 2023 | finance.yahoo.comIs Curis (NASDAQ:CRIS) In A Good Position To Deliver On Growth Plans?June 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 9, 2023 | markets.businessinsider.comCuris (CRIS) Gets a Buy from JonesTradingMay 4, 2023 | finance.yahoo.comCuris Provides First Quarter 2023 Business UpdateApril 27, 2023 | finance.yahoo.comCuris to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023April 17, 2023 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For GrowthApril 8, 2023 | seekingalpha.comCuris to grant stock options for 135.45K shares to new hireJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...April 7, 2023 | nasdaq.comCuris, Inc. Common Stock (CRIS)April 3, 2023 | finance.yahoo.comCuris to Present at Upcoming Healthcare Conferences in AprilMarch 17, 2023 | benzinga.comCuris's Return On Capital Employed OverviewMarch 14, 2023 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2022 Earnings Call TranscriptMarch 13, 2023 | finance.yahoo.comQ4 2022 Curis Inc Earnings CallMarch 13, 2023 | finance.yahoo.comCuris (CRIS) Reports Q4 Loss, Misses Revenue EstimatesMarch 13, 2023 | finance.yahoo.comCuris Provides Fourth Quarter 2022 Business UpdateMarch 13, 2023 | markets.businessinsider.comWhat Wall Street expects from Curis's earningsMarch 9, 2023 | finance.yahoo.comCuris Reschedules Fourth Quarter 2022 Business Update and Conference CallMarch 2, 2023 | finance.yahoo.comCuris to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023January 20, 2023 | finance.yahoo.comInvestors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the last five yearsDecember 12, 2022 | finance.yahoo.comCuris Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDSDecember 5, 2022 | prnewswire.comCuris to Host Webcast to Discuss Updated Emavusertib Clinical Data in LeukemiaNovember 12, 2022 | finance.yahoo.comCuris Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finance.yahoo.comThis biotech just laid off 30% of its staff. The CEO called the move 'counterintuitive'November 9, 2022 | finance.yahoo.comCuris (CRIS) Reports Q3 Loss, Misses Revenue EstimatesNovember 9, 2022 | finance.yahoo.comHere's Why We're Watching Curis' (NASDAQ:CRIS) Cash Burn SituationNovember 9, 2022 | finance.yahoo.comCuris Provides Third Quarter 2022 Business UpdateSee More Headlines CRIS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRIS Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CRIS CUSIP23126910 CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+990.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,670,000.00 Net Margins-501.08% Pretax Margin-501.08% Return on Equity-103.76% Return on Assets-45.81% Debt Debt-to-Equity RatioN/A Current Ratio9.67 Quick Ratio9.67 Sales & Book Value Annual Sales$10.16 million Price / Sales7.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book1.72Miscellaneous Outstanding Shares96,620,000Free Float90,502,000Market Cap$79.71 million OptionableOptionable Beta2.94 Social Links Key ExecutivesJames E. DentzerPresident, Chief Executive Officer & DirectorDiantha DuvallCFO, Treasurer & Chief Accounting OfficerMark W. NoelVP-Technology Management & Intellectual PropertyRobert E. MartellHead-Research & DevelopmentReinhard von RoemelingSenior Vice President-Clinical DevelopmentKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSSangamo TherapeuticsNASDAQ:SGMOAcorda TherapeuticsNASDAQ:ACORCognition TherapeuticsNASDAQ:CGTXCardiff OncologyNASDAQ:CRDFView All CompetitorsInstitutional OwnershipMaverick Capital Ltd.Sold 16,467 shares on 5/15/2023Ownership: 5.733%Two Sigma Advisers LPSold 239,500 shares on 5/15/2023Ownership: 0.639%Two Sigma Investments LPBought 74,149 shares on 5/15/2023Ownership: 0.121%Bank of America Corp DEBought 40,583 shares on 5/12/2023Ownership: 0.116%Group One Trading L.P.Sold 2,100 shares on 5/12/2023Ownership: 0.000%View All Institutional Transactions CRIS Stock - Frequently Asked Questions Should I buy or sell Curis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks. What is Curis' stock price forecast for 2023? 2 Wall Street research analysts have issued 1 year price objectives for Curis' stock. Their CRIS share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 990.9% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts. How have CRIS shares performed in 2023? Curis' stock was trading at $0.55 on January 1st, 2023. Since then, CRIS stock has increased by 50.0% and is now trading at $0.8250. View the best growth stocks for 2023 here. When is Curis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CRIS earnings forecast. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $2.30 million during the quarter, compared to the consensus estimate of $2.49 million. Curis had a negative trailing twelve-month return on equity of 103.76% and a negative net margin of 501.08%. During the same period in the prior year, the business earned ($0.18) earnings per share. When did Curis' stock split? Curis shares reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK). What is Curis' stock symbol? Curis trades on the NASDAQ under the ticker symbol "CRIS." Who are Curis' major shareholders? Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (5.73%), Citigroup Inc. (1.90%), Renaissance Technologies LLC (1.68%), BlackRock Inc. (1.44%), Two Sigma Advisers LP (0.64%) and CM Management LLC (0.57%). View institutional ownership trends. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Curis' stock price today? One share of CRIS stock can currently be purchased for approximately $0.83. How much money does Curis make? Curis (NASDAQ:CRIS) has a market capitalization of $79.71 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. How can I contact Curis? Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501. This page (NASDAQ:CRIS) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.